



ImmuCast

Release Notes

v5.18.1



Support Services

For general support on this product, contact your system administrator or help desk. For up-to-date documentation, visit the STC Documentation Portal at <https://documentation.stchome.com/>.

Connect with Us on Social Media



Copyrights and Trademarks

© 2018 by Scientific Technologies Corporation (STC). All rights reserved.

This documentation describes the following: ImmuCast 5.18.1 (and IWeb Forecaster) release notes

No part of this publication may be altered, reproduced, transmitted, stored in a retrieval system, or translated into any human or computer language, in any form or by any means, electronic, mechanical, magnetic, optical, or otherwise, without the prior written permission of the copyright owner.

This document, along with any embedded media, is provided for informational purposes only. Scientific Technologies Corporation (STC) provides this material "as is" and does not assert that this document is error free. The information contained herein may not necessarily accurately represent the current or planned functions of the application, and may be subject to significant and frequent modification. Scientific Technologies Corporation (STC) may change this document, any embedded content, and the product described herein at any time. Any changes will be incorporated in new versions of this document.

Scientific Technologies Corporation (STC) recognizes the rights of the holders of all trademarks used in its publications.

This document may provide hyperlinks to third-party websites or access to third-party content. Links and access to third-party sites are provided for your convenience only. Scientific Technologies Corporation does not control, endorse, or guarantee third-party content and is not responsible for any content, associated links, resources or services associated with a third-party site. Scientific Technologies Corporation shall also not be liable for any loss or damage associated with your use of any third-party content. (20170829)

Table of Contents

- Introduction 1
- Apply the Patch 1
 - For ImmuCast (Stand-Alone Forecaster) 1
 - For IWeb Only..... 2
- Age Groups Affected by this Release 2
- Ticket Details 3
- Product Documentation..... 11

Introduction

This release contains schedule changes that may affect the group of patients you select to be reforecasted. Detailed descriptions and test cases follow below in the ticket descriptions.

Please note that testing scenarios do not have a grace period applied.

Also note that Forecast, Forecaster, and ImmuCast are used interchangeably throughout this document.

Apply the Patch

Apply the patch by executing either the included `forecast.bat` or `forecast.sh` file. Prior forecast patches through version 5.17.10 should have already been applied. Log files, which are created in the same folder from where the patch is executed, can be reviewed for errors.

To determine the current version of ImmuCast, execute this statement from SQLPlus:

```
SQL> select max(version) from h33_forecast_version where insert_stamp =  
(select max(insert_stamp) from h33_forecast_version);
```

If the version number returned is not 5.17.10 or later, download and apply the previous patches prior to applying this patch. If any of the prior 5.17.x patches were not applied, edit the `forecast.bat` file (or `forecast.sh` if applying the batch with the shell script) and uncomment any lines with a later version number than the version number returned by your query so that they can be applied to the database. Log files are created in the folder from where the patch is executed and can be reviewed for errors.

For example, if the patch for 5.17.10 was not applied, uncomment that line in the file to include it when the patch is executed:

```
REM sqlplus H33ASIIS/ASIIS@SIIS @forecast_patch5_17_10.sql
```

After applying the patch, restart Tomcat to enable and cache any new vaccine codes into memory.

For ImmuCast (Stand-Alone Forecaster)

A Tomcat restart is required after applying this patch.

For IWeb Only

The database should be reforecast when there have been multiple changes to forecasting. Please be aware that this can affect a large number of patients and is best accomplished over a weekend.

IWeb versions prior to 5.17.5.2: Patients that are marked for forecast may interfere with the immediate deduplication of HL7 messages, because patients belonging to a particular organization will also be picked up by that organization's immediate deduplication session. IWeb version 5.17.5.2 or later will not affect the deduplication of HL7 messages.

After applying the database patch, log in to SQLPlus as the H33ASIIS user. Execute the H33_MARK_FORECAST procedure (`SQL> exec h33_mark_forecast`) to flag patient records to be reforecast. The procedure may also be run for a specific birth date range. For IWeb 5.17.5.2 or later, forecasting is run during the regular nightly deduplication processes.

Age Groups Affected by this Release

If your database will be reforecast for this release, the following are age ranges that we believe to be most affected by the changes in this release. You may wish to limit your reforecast to these age ranges to limit the scope of your reforecast. Based on the information below, the range for reforecasting would be 0 to 24 years of age. Based on your experience and knowledge of your patients, you may choose a different age range.

Zoster – Age 50+ years

Ticket Details

The following lists the detailed information about each of the tickets addressed in this version.

Ticket #	Description																																			
FCAST-452 Affects all clients	CVX code updates from IIS: Current HL7 Standard Code Set CVX -- Vaccines Administered <table border="1" data-bbox="466 500 1730 1198"> <thead> <tr> <th data-bbox="466 500 575 591">CVX Code</th> <th data-bbox="575 500 858 591">CVX Short Description</th> <th data-bbox="858 500 1278 591">Full Vaccine Name</th> <th data-bbox="1278 500 1480 591">Vaccine Status</th> <th data-bbox="1480 500 1730 591">Update Date</th> </tr> </thead> <tbody> <tr> <td data-bbox="466 591 575 654">187</td> <td data-bbox="575 591 858 654">zoster recombinant</td> <td data-bbox="858 591 1278 654">zoster vaccine recombinant</td> <td data-bbox="1278 591 1480 654">Active</td> <td data-bbox="1480 591 1730 654">10/27/2017</td> </tr> <tr> <td data-bbox="466 654 575 745">188</td> <td data-bbox="575 654 858 745">zoster, unspecified formulation</td> <td data-bbox="858 654 1278 745">zoster vaccine, unspecified formulation</td> <td data-bbox="1278 654 1480 745">Inactive</td> <td data-bbox="1480 654 1730 745">10/27/2017</td> </tr> <tr> <td data-bbox="466 745 575 867"></td> <td data-bbox="575 745 858 867">RSV-Mab(new)</td> <td data-bbox="858 745 1278 867">Respiratory syncytial virus monoclonal antibody (montavizumab), intramuscular</td> <td data-bbox="1278 745 1480 867">Never Active</td> <td data-bbox="1480 745 1730 867">10/27/2017</td> </tr> <tr> <td data-bbox="466 867 575 958">32</td> <td data-bbox="575 867 858 958">meningococcal MPSV4</td> <td data-bbox="858 867 1278 958">meningococcal polysaccharide vaccine (MPSV4)</td> <td data-bbox="1278 867 1480 958">Inactive</td> <td data-bbox="1480 867 1730 958">10/27/2017</td> </tr> <tr> <td data-bbox="466 958 575 1107">09</td> <td data-bbox="575 958 858 1107">Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed</td> <td data-bbox="858 958 1278 1107">tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)</td> <td data-bbox="1278 958 1480 1107">Active</td> <td data-bbox="1480 958 1730 1107">10/27/2017</td> </tr> <tr> <td data-bbox="466 1107 575 1198">189</td> <td data-bbox="575 1107 858 1198">Hep B, adjuvanted</td> <td data-bbox="858 1107 1278 1198">Hepatitis B vaccine (recombinant), adjuvanted</td> <td data-bbox="1278 1107 1480 1198">Active</td> <td data-bbox="1480 1107 1730 1198">10/27/2017</td> </tr> </tbody> </table>	CVX Code	CVX Short Description	Full Vaccine Name	Vaccine Status	Update Date	187	zoster recombinant	zoster vaccine recombinant	Active	10/27/2017	188	zoster, unspecified formulation	zoster vaccine, unspecified formulation	Inactive	10/27/2017		RSV-Mab(new)	Respiratory syncytial virus monoclonal antibody (montavizumab), intramuscular	Never Active	10/27/2017	32	meningococcal MPSV4	meningococcal polysaccharide vaccine (MPSV4)	Inactive	10/27/2017	09	Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed	tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)	Active	10/27/2017	189	Hep B, adjuvanted	Hepatitis B vaccine (recombinant), adjuvanted	Active	10/27/2017
CVX Code	CVX Short Description	Full Vaccine Name	Vaccine Status	Update Date																																
187	zoster recombinant	zoster vaccine recombinant	Active	10/27/2017																																
188	zoster, unspecified formulation	zoster vaccine, unspecified formulation	Inactive	10/27/2017																																
	RSV-Mab(new)	Respiratory syncytial virus monoclonal antibody (montavizumab), intramuscular	Never Active	10/27/2017																																
32	meningococcal MPSV4	meningococcal polysaccharide vaccine (MPSV4)	Inactive	10/27/2017																																
09	Td (adult), 2 Lf tetanus toxoid, preservative free, adsorbed	tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use (2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid)	Active	10/27/2017																																
189	Hep B, adjuvanted	Hepatitis B vaccine (recombinant), adjuvanted	Active	10/27/2017																																

Ticket #	Description																				
	<p>IWeb only: MVX code updates from IIS: Current HL7 Standard Code Set MVX – Manufacturers of Vaccines</p> <table border="1"> <thead> <tr> <th>MVX Code</th> <th>Manufacturer Name</th> </tr> </thead> <tbody> <tr> <td>DSI</td> <td>Dispensing Solutions</td> </tr> <tr> <td>REB</td> <td>Rebel Distributors</td> </tr> <tr> <td>VET</td> <td>Vetter Pharma Fertigung GmbH & Co. KG</td> </tr> </tbody> </table>	MVX Code	Manufacturer Name	DSI	Dispensing Solutions	REB	Rebel Distributors	VET	Vetter Pharma Fertigung GmbH & Co. KG												
MVX Code	Manufacturer Name																				
DSI	Dispensing Solutions																				
REB	Rebel Distributors																				
VET	Vetter Pharma Fertigung GmbH & Co. KG																				
FCAST-453 Affects all clients	ACIP Shingrix Recommendations: Zoster recombinant (Shingrix - CVX 187) will be the preferred zoster vaccine and is recommended at 50 years of age. The ACIP recommends two doses of Shingrix separated by 2 months. For patients who previously received Zoster Vaccine Live, two doses of Shingrix are recommended. https://www.cdc.gov/mmwr/volumes/67/wr/mm6703a5.htm?s_cid=mm6703a5_e https://www.cdc.gov/mmwr/volumes/67/wr/pdfs/mm6703a5-H.pdf																				
FCAST-395 HDTN-778 Affects IWeb & MT Only	Tdap: The forecast for a dose of pertussis at >= 7 years of age was not being separated to Tdap when a pediatric DT, tetanus toxoid adsorbed, or tetanus toxoid not adsorbed was present in the immunization history.																				
	<table border="1"> <thead> <tr> <th>Scenario</th> <th>DOB</th> <th>Gen-der</th> <th>Antigen</th> <th>Vacc Date</th> <th>Valid (Y)</th> <th>Rec Date</th> <th>Min Date</th> <th>Past Due</th> <th>Comments</th> </tr> </thead> <tbody> <tr> <td>Pediatric DT in immunization history</td> <td>07/04/2003</td> <td>M</td> <td>DTaP (CVX 106)</td> <td>09/03/2003</td> <td>Y</td> <td></td> <td></td> <td></td> <td></td> </tr> </tbody> </table>	Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments	Pediatric DT in immunization history	07/04/2003	M	DTaP (CVX 106)	09/03/2003	Y				
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments												
Pediatric DT in immunization history	07/04/2003	M	DTaP (CVX 106)	09/03/2003	Y																

Ticket #		Description							
Scenario	DOB	Gender	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
			DTaP (CVX 106)	12/02/2003	Y				
			DTaP (CVX 106)	01/26/2004	Y				
			DTaP (CVX 106)	01/07/2005	Y				
			DTaP (CVX 106)	07/16/2008	Y				
			DT Pediatric (CVX 28)	08/26/2014	Y	08/27/2014	08/27/2014	09/26/ 2014	Tdap forecast
Td adsorbed immunization history	07/24/2003	M	DTaP (CVX 106)	09/03/2003	Y				
			DTaP (CVX 106)	12/02/2003	Y				

Ticket #		Description							
Scenario	DOB	Gender	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
			DTaP (CVX 106)	01/26/2004	Y				
			DTaP (CVX 106)	01/07/2005	Y				
			DTaP (CVX 106)	07/16/2008	Y				
			Tetanus toxoid adsorbed (CVX 35)	08/26/2014	Y	08/27/2014	08/27/2014	09/26/ 2014	Tdap forecast
Td not adsorbed in immunization history	07/04/2003	M	DTaP (CVX 106)	09/03/2003	Y				
			DTaP (CVX 106)	12/02/2003	Y				

Ticket #		Description							
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
			DTaP (CVX 106)	01/26/2004	Y				
			DTaP (CVX 106)	01/07/2005	Y				
			DTaP (CVX 106)	07/16/2008	Y				
			Tetanus toxoid not adsorbed (CVX 142)	08/26/2014	Y	08/27/2014	08/27/2014	09/26/ 2014	Tdap forecast
FCAST-441 HDWA-3068 Affects all clients		Patient DTaP/Tdap forecast was not moved to 7 years of age for current age based on today's date.							
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
DTaP/Tdap	09/06/2010	F	DTaP-Hib-IPV (CVX 120)	11/18/2010	Y				

Ticket #		Description							
Scenario	DOB	Gender	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
			DTaP-Hib-IPV (CVX 120)	01/08/2011	Y				
			DTaP-Hib-IPV (CVX 120)	03/07/2011	Y				
			DTaP (CVX 20)	03/07/2014	Y	09/06/2017	09/06/2017	10/06/2017	Tdap forecast
FCAST-439 HDAZ-858	Influenza – For children < 9 years of age, the influenza forecast was not considering doses administered prior to July 1, 2010 towards the 2 previous doses count.								
Affects all clients									
Scenario	DOB	Gender	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
Influenza	06/01/2009	F	Influenza (CVX 141)	12/21/2009	Y				
			Influenza (CVX 141)	04/12/2010	Y				

Ticket #		Description							
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
			Influenza (CVX 141)	09/13/2017	Y	10/01/2018	07/01/2018		
FCAST-454 HDWA-3065	Update invalid reasons for OPV to display at invalid with reason of "OPV bivalent and OPV monovalent are not acceptable for Polio series." if vaccination date is >= 04/01/2016. Administration dates prior to 04/01/2016 will display another reason type.								
Affects all clients									
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
OPV invalid reasons	01/01/2014	F	MMR	01/01/2015	Y				
			OPV (CVX 02)	01/01/2015	N				Invalid Vaccination: Live vaccines not administered on same date must be separated by 28 days.
OPV invalid reasons	01/01/2014	F	MMR (CVX 03)	04/01/2016	Y				

Ticket #		Description							
			OPV (CVX 02)	04/02/2016	N				Invalid Vaccination: OPV bivalent and OPV monovalent are not acceptable for Polio series.
FCAST-360 HDWA-2877	<p>HPV prior to the Dec 2016 MMWR required 24 weeks between doses 1 and 3. The forecast was only enforcing 16 weeks. Will change to enforce 24 weeks for those doses.</p> <p>Affects all clients https://www.cdc.gov/vaccines/schedules/downloads/past/2015-adult.pdf</p> <p>A complete series for either HPV4 or HPV2 consists of 3 doses. The second dose should be administered 4 to 8 weeks (minimum interval of 4 weeks) after the first dose; the third dose should be administered 24 weeks after the first dose and 16 weeks after the second dose (minimum interval of at least 12 weeks).</p>								
Scenario	DOB	Gen-der	Antigen	Vacc Date	Valid (Y)	Rec Date	Min Date	Past Due	Comments
HPV Historical Schedule (2015)	07/10/2000	F	HPV quadrivalent (CVX 62)	07/10/2015	Y				
			HPV quadrivalent (CVX 62)	08/10/2015	Y				
			HPV quadrivalent (CVX 62)	11/10/2015	N				Invalid Vaccination: Minimum interval from Dose 1 not met.

Product Documentation

Product documentation is located on the STC Documentation Portal:
<https://documentation.stchome.com/>.

The following documents are available for this version of ImmuCast:

- ImmuCast 5.18.1 User Guide